N Engl J Med January 2025 PMID 39282902

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.

Andrea B Apolo, Karla V Ballman, Guru Sonpavde, Stephanie Berg, William Y Kim, Rahul Parikh, Min Yuen Teo, Randy F Sweis, Daniel M Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W Kim, Mehmet Asim Bilen, Bradley McGregor

Full text PDF Download social card

Mentions

234

Peak: 71 in Sep 2024

across 6 sources since Sep 2024

Extended reach

3,992,965

potential audience

Total likes

450

Video views

603

Mentions per month

Sep 2024 – Nov 2025

Where it's discussed

X / Twitter193 posts
News28 articles
Blogs6 articles
YouTube3 videos
Bluesky2 posts
Facebook2 posts

AI synopsis

What people are saying

The overall tone is highly positive and invested, with examples like colleagues congratulating Dr. Andrea Apolo and sharing detailed data such as the median DFS of 29.6 months versus 14.2 months, demonstrating active discussion and recognition of the study's importance. Words like 'significant,' 'brilliant work,' and 'game changer' highlight both the high interest and perceived impact of this research in advancing cancer therapy.

AgreementStrong agreement

Most comments praise the significance of the study, highlighting the positive results for pembrolizumab in extending disease-free survival.

InterestHigh interest

Discussions reflect high curiosity and enthusiasm, with mentions of detailed trial results and the potential for clinical impact.

EngagementHigh engagement

Posts show deep engagement through sharing articles, summarizing findings, and expressing support for the researchers and their work.

ImpactHigh impact

Several posts emphasize the groundbreaking nature of the research and its potential to influence bladder cancer treatment protocols.

Abstract in brief

Muscle-invasive urothelial carcinoma is a challenging type of cancer with high recurrence rates, and the effectiveness of pembrolizumab as an adjuvant therapy post-surgery remains uncertain.
In a phase 3 trial involving 702 patients, those receiving pembrolizumab showed significantly longer disease-free survival (29.6 months) compared to those under observation (14.2 months).
However, the pembrolizumab group experienced a higher incidence of severe adverse events (50.6%) compared to the observation group (31.6%).

Read the full abstract

All mentions

Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Carcinoma

A Phase 3 trial shows pembrolizumab enhances disease-free survival in high-risk muscle-invasive urothelial carcinoma patients post-surgery, serving as an alternative to chemotherapy, despite increased adverse events.

CONECTIMED · Feb 10, 2025 303 views

Recent Advances in Bladder Cancer Treatment and Research Progress

There is significant progress in bladder cancer. Dr. Andrea Apolo discusses advancements in urothelial cancer therapy, including checkpoint inhibition breakthroughs and treatment strategies for different stages, based…

Chadi Nabhan and Healthcare Unfiltered · Nov 19, 2024 168 views

Pembrolizumab Improves Outcomes in Muscle-Invasive Urothelial Carcinoma

This video discusses a phase 3 trial showing pembrolizumab significantly extends disease-free survival in muscle-invasive urothelial carcinoma, despite higher adverse event rates. Learn about the effectiveness and risks…

CONECTIMED · Feb 10, 2025 132 views

GUMDROP

@GUMDROPtrials · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 8, 2025 · 6 shares · 400 followers View post →

Eileen M O’Reilly

@EileenMOReilly · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 7, 2025 · 6 shares · 6,397 followers View post →

Neeraj Agarwal, MD, FASCO

@neerajaiims · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 7, 2025 · 6 shares · 16,711 followers View post →

Alan Tan

@alantanmd · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 7, 2025 · 6 shares · 2,210 followers View post →

David H Aggen, MD PhD

@Dr_Aggen · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 7, 2025 · 6 shares · 805 followers View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @ALLIANCE_org: Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrol…

Nov 7, 2025 · 6 shares · 8,901 followers View post →

Alliance for Clinical Trials in Oncology

@ALLIANCE_org · X

Kudos to .@apolo_andrea of @theNCI for one of the Most Significant @ALLIANCE_org Manuscripts 2024-2025! "Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma" in NEJM #AllianceFall25 #NCI #NCTN #AMBASSADOR #AllianceA031501 https://t.co/LWdP5qtQ8R

Nov 7, 2025 · 9 likes · 6 shares · 7,528 followers View post →

Alliance for Clinical Trials in Oncology

@alliance-org.bsky.social · Bluesky

Kudos to Andrea Apolo, MD, of the National Cancer Institute, for one of the Most Significant Alliance Manuscripts 2024-2025! "Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma" in NEJM #AllianceFall25 #NCI #NCTN #AMBASSADOR #AllianceA031501

Nov 7, 2025 View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @Timothee_MD: This table is from AMBASSADOR https://t.co/vO4uyokEIs Do we know how many patients received "any systemic" therapy ? (her…

Oct 24, 2025 · 1 share · 8,901 followers View post →

Timothée Olivier, MD

@Timothee_MD · X

This table is from AMBASSADOR https://t.co/vO4uyokEIs Do we know how many patients received "any systemic" therapy ? (here 12 received radiation, but there might be overlap) Thanks a lot! @apolo_andrea @PGrivasMDPhD https://t.co/pin5z6mWtl

Oct 23, 2025 · 8 likes · 1 share · 2,751 followers View post →

Ignacio Rguez. Gomez

@urogomez_ · X

RT @nataliagandur:

Sep 29, 2025 · 44 shares · 891 followers View post →

Lu ZHANG

@LuZ03FaPCa · X

RT @nataliagandur:

Sep 29, 2025 · 44 shares · 53 followers View post →

will_oncology

@will_oncology · X

RT @nataliagandur:

Sep 29, 2025 · 44 shares · 334 followers View post →

Laura Bolaño G.

@laurabolgue · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 485 followers View post →

Yael Waknine

@yaelwaknine · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 221 followers View post →

Ricardo Carvalho

@rcarvalhoonco · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 2,270 followers View post →

ROSA GARCIA

@DOCRO74 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 134 followers View post →

Alan Reyes-M.D

@dralanreyesonco · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 1,356 followers View post →

Ali Alshehri

@prson55 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 263 followers View post →

RUTH OSORIO

@draruthosorio · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 12 followers View post →

Yoshiyuki Miyazawa, MD, PhD

@yossy_myz · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 335 followers View post →

Nelson Canales

@regidor26 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 72 followers View post →

Wagner Parra-Paladines

@WagnerParra2 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 62 followers View post →

Giovanna Pecoraro

@giovanna55701 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 110 followers View post →

Miri

@Miri_1425 · X

RT @nataliagandur:

Sep 28, 2025 · 44 shares · 72 followers View post →

Alvaro

@Almonca_o_O · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 430 followers View post →

ONCO BRUNO

@brunolarvol · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 7,363 followers View post →

Tae Hoon Lee, MD, PhD

@lthoon0420 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 102 followers View post →

Elad Sharon

@EladSharonMD · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 3,890 followers View post →

Dr Celestino Gutiérrez González MD

@CelestinoGutirr · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 11,332 followers View post →

Tobias Büttner

@tobiasmbuettner · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 46 followers View post →

Stefania Colasanti

@Stefani19753108 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 847 followers View post →

Daniel Saidian MD

@DanielSaidian · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 98 followers View post →

Carlos Salazar

@DrSalazarMejia · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 945 followers View post →

Petros Grivas

@PGrivasMDPhD · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 18,579 followers View post →

rmnardone

@rmnardone · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 346 followers View post →

nel cuevas muñoz

@MunozNel · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 148 followers View post →

Almansour

@malmansour81 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 214 followers View post →

Hansel Alemán T

@hansel8aleman · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 978 followers View post →

Catalina Pogany

@pogany54 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 684 followers View post →

Alfonso Gómez de Liaño

@Uro_Oncologist · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 524 followers View post →

Dr Hector Caballero Urologo

@Hector03051991 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 178 followers View post →

د.عبدالله علي الشرم

@dralsharm · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 3,912 followers View post →

Ray Manneh Kopp

@raymanneh · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 1,404 followers View post →

Ahmad Mery

@docahmadmed · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 6 followers View post →

Jun Gong

@jgong15 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 1,670 followers View post →

drfeelgood

@drfeelgood049 · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 130 followers View post →

Wesley Verla

@wesley_verla · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 404 followers View post →

Dr. SN Sinha

@DrSatyendra4u · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 171 followers View post →

OncoAlert

@OncoAlert · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 40,458 followers View post →

Dong Nguyen

@DongNguyeb · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 2,142 followers View post →

Yuan James Rao

@yuanjamesrao · X

RT @nataliagandur:

Sep 27, 2025 · 44 shares · 2,316 followers View post →

Dra. María Natalia Gandur Quiroga

@nataliagandur · X

Sep 27, 2025 · 136 likes · 44 shares · 2,965 followers View post →

Rafael Correa Cano MD, MSc.

@Rf_Correa · X

RT @ALLIANCE_org: Hats off to @ALLIANCE_org @apolo_andrea @NCI and Jennifer Chan, MD, MPH @DanaFarber for publishing results from Alliance…

Sep 26, 2025 · 5 shares · 1,008 followers View post →

Alliance for Clinical Trials in Oncology

@ALLIANCE_org · X

Hats off to @ALLIANCE_org @apolo_andrea @NCI and Jennifer Chan, MD, MPH @DanaFarber for publishing results from Alliance CABINET (A021602) #NETS and AMBASSADOR (A031501) #bladdercancer trials in NEJM: https://t.co/98Tn1CHy35 & https://t.co/bIWtQMupZO @nejm #UAM25 #NCI #NCTN https://t.co/fkzjBeHinQ

Sep 26, 2025 · 11 likes · 5 shares · 7,528 followers View post →

Alliance for Clinical Trials in Oncology

@ALLIANCE_org · X

Hats off to Alliance researchers @apolo_andrea @NCI et al and Jennifer Chan, MD, MPH @DanaFarber et al for publishing results on neuroendocrine tumors and urothelial cancer in the New England Journal of Medicine. https://t.co/98Tn1CHy35 & https://t.co/bIWtQMupZO @nejm #UAM25 https://t.co/ovXLkguTnz

Sep 3, 2025 · 5 likes · 2 shares · 7,479 followers View post →

Dr. Poetic

@Dr_Doc_ · X

המחקר עליו מבוסס מתן הטיפול המשלים בקיטורדה https://t.co/9xKW2qmlKN https://t.co/AGcDGP0Hec

Jun 9, 2025 · 3,020 followers View post →

Ali ihsan OLUK

@KasosMete · X

RT @tuttsakhil: Adjuvant Pembrolizumab versus Observation in Muscle-invasive Urothelial Carcinoma @EUplatinum https://t.co/oB98fkQbKn

Apr 18, 2025 · 1 share · 554 followers View post →

Dr Akhil Santhosh

@tuttsakhil · X

Adjuvant Pembrolizumab versus Observation in Muscle-invasive Urothelial Carcinoma @EUplatinum https://t.co/oB98fkQbKn

Apr 17, 2025 · 6 likes · 1 share · 885 followers View post →

Grupo Medicable

@GrupoMedicable · X

Conectimed, plataforma para la actualización médica continua. Notimed. Pembrolizumab en el tratamiento del carcinoma urotelial con invasión muscular. https://t.co/CHSIbDHUJW #salud #medicos #ciencia #medicina #industriafarmaceutica #tratamientos #Conectimed

Feb 10, 2025 · 1 followers View post →

Mouna AYADI

@MounaAYADI79021 · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Feb 7, 2025 · 18 shares · 18 followers View post →

がむしゃら院長

@gamushara_incho · X

尿路上皮癌は、腎盂、尿管、膀胱、尿道などの尿路の上皮（粘膜）に発生する悪性腫瘍高リスク筋層浸潤性尿路上皮癌でペムブロリズマブが無病生存期間を有意に延長。術後補助療法として有望。#がん治療 #免疫療法 #臨床試験 https://t.co/U8TDmwC75S https://t.co/52l8VT11tC

Jan 31, 2025 · 35 followers View post →

Mellodi Zintkala

@MZintkala · X

RT @tompowles1: @apolo_andrea I hope things settle quickly for you Andrea and you can continue your brilliant work. https://t.co/lMFKB30XxC

Jan 25, 2025 · 4 shares · 5,578 followers View post →

Fesquet didier

@didierfesquet · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/odxQLFdNDt "receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year "....thats a lot

Jan 25, 2025 · 248 followers View post →

Fesquet didier

@didierfesquet · X

"receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year

Jan 25, 2025 · 248 followers View post →

Trevor "Trev" McKee Achilles

@MrTAchilles · X

RT @tompowles1: @apolo_andrea I hope things settle quickly for you Andrea and you can continue your brilliant work. https://t.co/lMFKB30XxC

Jan 25, 2025 · 4 shares · 22,360 followers View post →

GUMDROP

@GUMDROPtrials · X

RT @tompowles1: @apolo_andrea I hope things settle quickly for you Andrea and you can continue your brilliant work. https://t.co/lMFKB30XxC

Jan 24, 2025 · 4 shares · 396 followers View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @tompowles1: @apolo_andrea I hope things settle quickly for you Andrea and you can continue your brilliant work. https://t.co/lMFKB30XxC

Jan 24, 2025 · 4 shares · 8,891 followers View post →

Tom Powles

@tompowles1 · X

@apolo_andrea I hope things settle quickly for you Andrea and you can continue your brilliant work. https://t.co/lMFKB30XxC

Jan 24, 2025 · 48 likes · 4 shares · 12,723 followers View post →

UChicago Cancer

@uchicagocancer.bsky.social · Bluesky

New paper alert!

Jan 21, 2025 · 3 likes · 1 share View post →

University of Chicago Hematology/Oncology

@UChicagoHemOnc · X

New paper alert!

Jan 21, 2025 · 3 likes · 824 followers View post →

Petros Grivas

@PGrivasMDPhD · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Jan 16, 2025 · 18 shares · 18,339 followers View post →

Ippokratis Korantzis, Medical Oncologist, MD, PhD

@newsincancer · X

Adjuvant #Pembrolizumab versus Observation in Muscle-Invasive #UrothelialCarcinoma | New England Journal of Medicine https://t.co/gaVzLjmOW7

Jan 13, 2025 · 285 followers View post →

Saludteca

@Saludteca · X

Pembrolizumab en el carcinoma urotelial invasivo en músculo https://t.co/p9gmVyd30j

Jan 10, 2025 · 2,000 followers View post →

Stefania Colasanti

@Stefani19753108 · X

RT @JankovicK: ✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 10, 2025 · 5 shares · 812 followers View post →

Anant Jawahar Raina

@AJRaina01 · X

RT @JankovicK: ✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 10, 2025 · 5 shares · 529 followers View post →

MEDTRACK

@OncoReporte · X

RT @JankovicK: ✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 10, 2025 · 5 shares · 949 followers View post →

Gil Morgan, MD

@weoncologists · X

RT @JankovicK: ✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 10, 2025 · 5 shares · 16,327 followers View post →

OncoAlert

@OncoAlert · X

RT @JankovicK: ✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 10, 2025 · 5 shares · 39,835 followers View post →

Kristina Jankovic, MD

@JankovicK · X

✨AMBASSADOR✨: Adjuvant #Pembrolizumab

Jan 9, 2025 · 11 likes · 5 shares · 984 followers View post →

Bichoy Gabra, R.Ph., Ph.D.

@BichoyGabra · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma This study has shown that, among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than https://t.co/9t5EM2MTvH

Jan 9, 2025 · 264 followers View post →

Shicheng Guo

@ShihchengGuo · X

Phase 3 trial: Adjuvant #Pembrolizumab vs. observation in 1:1 randomization for high-risk muscle-invasive urothelial carcinoma. 200 mg every 3 weeks for 1 year.

Jan 9, 2025 · 495 followers View post →

Sergio Casillas

@scasillasmd · X

RT @milanhoraplzen: Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survi…

Jan 7, 2025 · 6 shares · 104 followers View post →

Dr Hector Caballero Urologo

@Hector03051991 · X

RT @milanhoraplzen: Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survi…

Jan 7, 2025 · 6 shares · 180 followers View post →

Karim Haddad

@kh_reader_onco · X

RT @milanhoraplzen: Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survi…

Jan 7, 2025 · 6 shares · 21 followers View post →

nel cuevas muñoz

@MunozNel · X

RT @milanhoraplzen: Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survi…

Jan 7, 2025 · 6 shares · 145 followers View post →

refaat abusamra

@refaatabusamra · X

RT @milanhoraplzen: Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survi…

Jan 7, 2025 · 6 shares · 341 followers View post →

Milan Hora

@milanhoraplzen · X

Adjuvant Pembrolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma after radical surgery, disease-free survival 29.6 vs 14.2 months, hazard ratio for disease progression / death 0.73; AMBASSADOR trial, N Engl J Med. 2025 Jan 2;392(1):45-55 https://t.co/xeMjTxKQLQ https://t.co/eHuvyiHu8g

Jan 7, 2025 · 16 likes · 6 shares · 1,278 followers View post →

ONCOassist® | The go-to oncology app

@ONCOassist · X

Jan 6, 2025 · 4 likes · 4,305 followers View post →

Luis R Velásquez M

@chaccalt · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 5, 2025 · 10 shares · 317 followers View post →

Adela

@adelapoite · X

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/baKp5tBNzM

Jan 3, 2025 · 2 likes · 1,234 followers View post →

Adela

@adelapoite · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/nyATuLGuWd

Jan 3, 2025 · 2 likes · 1,234 followers View post →

CarinthianDoc

@CarinthianDoc · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 2, 2025 · 10 shares · 509 followers View post →

BMJ Oncology

@BMJOncology · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 2, 2025 · 10 shares · 2,533 followers View post →

ONCO BRUNO

@brunolarvol · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 2, 2025 · 10 shares · 7,253 followers View post →

食のバケモノ

@Sugi96F · X

RT @ShingoHatakeya1: MIUCに対するアジュバントPembrolizumabの成績がNEJMに出ましたね。 NACあり群がアジュバントニボより多い（64% va. 43%）やはり上部尿路はDFS悪い傾向あり！？ N Engl J Med 2025;392:…

Jan 2, 2025 · 1 share · 134 followers View post →

Isaura R. Penin

@irodriguezpenin · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/P69KMbLXuY

Jan 2, 2025 · 622 followers View post →

AngryPhDstudent❗️❗️❗️

@ONNESHA092 · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 2, 2025 · 10 shares · 182 followers View post →

Higinio

@curabellas · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 2, 2025 · 10 shares · 1,043 followers View post →

Eric

@ericsophia12 · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 1, 2025 · 10 shares · 97 followers View post →

Kevin

@Kevin_Use11 · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 1, 2025 · 10 shares · 15 followers View post →

Shingo Hatakeyama

@ShingoHatakeya1 · X

MIUCに対するアジュバントPembrolizumabの成績がNEJMに出ましたね。 NACあり群がアジュバントニボより多い（64% va. 43%）やはり上部尿路はDFS悪い傾向あり！？ N Engl J Med 2025;392:45-55 DOI: 10.1056/NEJMoa2401726 https://t.co/HPlD2lgdIy

Jan 1, 2025 · 12 likes · 1 share · 2,352 followers View post →

Hema Baskarane

@hema_oncologist · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 1, 2025 · 10 shares · 258 followers View post →

上白石粗茶

@sochany · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Jan 1, 2025 · 10 shares · 388 followers View post →

NEJM

@NEJM · X

Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM3K4ct6X #Oncology https://t.co/x9xzoH4TPS

Jan 1, 2025 · 41 likes · 10 shares · 935,606 followers View post →

Чиж

@rough_fiddle · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 30, 2024 · 18 shares · 9 followers View post →

OncoAlert

@OncoAlert · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 30, 2024 · 18 shares · 39,835 followers View post →

Mrugal Doshi

@mrugaldoshi · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 29, 2024 · 18 shares · 54 followers View post →

Sumanta K. Pal, MD, FASCO

@montypal · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 29, 2024 · 18 shares · 21,843 followers View post →

Nazli Dizman

@NazliDizman · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 29, 2024 · 18 shares · 10,278 followers View post →

Anas Ghazi, MD, MPH

@Anas_AlGhazi · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 29, 2024 · 18 shares · 27 followers View post →

Vishwanath Hanchanale/ Robotic Urological Surgeon

@vishhanchanale · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 28, 2024 · 18 shares · 1,801 followers View post →

Mridul Khanna

@mridulkhanna91 · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 28, 2024 · 18 shares · 597 followers View post →

Praveen Pendyala, MD

@PPendyalaMD · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 27, 2024 · 18 shares · 314 followers View post →

Tom Powles

@tompowles1 · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 27, 2024 · 18 shares · 12,723 followers View post →

Cristiane D Bergerot

@crisbergerot · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 27, 2024 · 18 shares · 8,160 followers View post →

Fabio Schutz

@FabioSchutz78 · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 27, 2024 · 18 shares · 3,787 followers View post →

Elad Sharon

@EladSharonMD · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 26, 2024 · 18 shares · 3,831 followers View post →

Shilpa Gupta

@shilpaonc · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 26, 2024 · 18 shares · 8,135 followers View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @DrChoueiri: 7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months)…

Dec 26, 2024 · 18 shares · 8,891 followers View post →

Toni Choueiri, MD

@DrChoueiri · X

Dec 26, 2024 · 47 likes · 18 shares · 42,600 followers View post →

chadi nabhan MD, MBA, FACP

@chadinabhan · X

Advances in Bladder Cancer With Andrea Apolo https://t.co/BmgzFWh9ph via @YouTube My #HealthcareUnfiltered with @apolo_andrea is now on YouTube. What an inspiring episode on all advances and her recent work published in @NEJM

Nov 20, 2024 · 5 likes · 4 shares · 20,049 followers View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @ALLIANCE_org: Hats off to Alliance researchers @apolo_andrea @NCI et al and Jennifer Chan, MD, MPH @DanaFarber et al for Significant Al…

Nov 1, 2024 · 3 shares · 8,891 followers View post →

Alliance for Clinical Trials in Oncology

@ALLIANCE_org · X

Hats off to Alliance researchers @apolo_andrea @NCI et al and Jennifer Chan, MD, MPH @DanaFarber et al for Significant Alliance Publications in NEJM in September 2024! https://t.co/98Tn1CHy35 & https://t.co/bIWtQMupZO #AllianceFall24 #NCI #NCTN #CancerResearch https://t.co/5kgP1GAIbP

Nov 1, 2024 · 10 likes · 3 shares · 7,479 followers View post →

Cancer_Evolve

@cancer_evolve · X

BLADDER: adjuvant PD1 inhibition (pembrolizumab) improved disease free survival for patients with muscle invasive disease (median DFS for treatment versus placebo: 30 versus 14 months) https://t.co/ItaJaJ9xWr

Sep 30, 2024 · 369 followers View post →

Elad Sharon

@EladSharonMD · X

RT @NEJM: @myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 24, 2024 · 5 shares · 3,831 followers View post →

Jun Gong

@jgong15 · X

RT @NEJM: @myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 24, 2024 · 5 shares · 1,649 followers View post →

Dr. Andre R. Kydd

@DrAndreKydd · X

RT @NEJM: @myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 24, 2024 · 5 shares · 208 followers View post →

Andrea Apolo, M.D.

@apolo_andrea · X

RT @NEJM: @myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 24, 2024 · 5 shares · 8,891 followers View post →

Top Biomedical Science

@imedverse · X

RT @imedverse: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma @NEJM #ESMO24 #CSCO24 Read more https://…

Sep 24, 2024 · 1 share · 90,463 followers View post →

Taseen Haque

@haqueward · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 23, 2024 · 123 shares · 329 followers View post →

Andres Cervantes

@AndresC27622123 · X

RT @NEJM: @myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 23, 2024 · 5 shares · 4,660 followers View post →

NEJM

@NEJM · X

@myESMO Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR)

Sep 23, 2024 · 17 likes · 5 shares · 935,606 followers View post →

pinacol

@pinacol · X

【RCT】根治切除術後のハイリスクの筋肉浸潤性尿路上皮癌患者へのペムブロリズマブの投与は、経過観察と比較して、無病生存期間を延長させた。 #ペ読 https://t.co/BccB9LIgdT

Sep 22, 2024 · 1 like · 1,613 followers View post →

Cancer Agent

@Cancer_Agent · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma - https://t.co/LAdm6zZB2v https://t.co/OXL7y9lHIE

Sep 20, 2024 · 2,319 followers View post →

Isaura R. Penin

@irodriguezpenin · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/4QeHDYN0t0

Sep 19, 2024 · 1 like · 622 followers View post →

FabriceAndre

@FAndreMD · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 17, 2024 · 11 shares · 15,114 followers View post →

Javier Pérez Ardavín

@jpardavin · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 525 followers View post →

Javier Pérez Ardavín

@jpardavin · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 525 followers View post →

ilyas sahin, MD

@ilyassahinMD · X

* https://t.co/YUME0Ukl1L

Sep 16, 2024 · 1 like · 20,806 followers View post →

Joseph KAMTCHUM TATUENE

@JTatuene · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 609 followers View post →

Diane Newman

@DrDianeNewman · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 152 followers View post →

Magdalena Görtz

@GortzMagdalena · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 108 followers View post →

Ana Medina

@amedinacol · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 2,326 followers View post →

Gianluca Giannarini

@GGiannarini · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 2,541 followers View post →

anna scavuzzo

@annascavuzzo2 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 202 followers View post →

Ghalib Jibara

@GhalibJibara · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 296 followers View post →

Wagner Parra-Paladines

@WagnerParra2 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 52 followers View post →

gilberto lopes

@GlopesMd · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 37,600 followers View post →

gilberto lopes

@GlopesMd · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 37,600 followers View post →

KOL Pulse AI

@KolPulseAI · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 951 followers View post →

Top Biomedical Science

@imedverse · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma @NEJM #ESMO24 #CSCO24 Read more https://t.co/DDdZy9NCXz https://t.co/mOPIkQJm0j

Sep 16, 2024 · 1 like · 1 share · 90,463 followers View post →

Top Biomedical Science

@imedverse · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 90,463 followers View post →

Vikas Singh, MD, MBA, FACP

@VikasSinghMD · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 414 followers View post →

Giovanni Maria Iannantuono

@GMIannantuonoMD · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 122 followers View post →

Abstream

@abstreamme · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma #science #publication #research #publications https://t.co/jicQu9hbx5

Sep 16, 2024 · 788 followers View post →

Luca Orecchia

@luca_orecchia · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 301 followers View post →

Abstream

@abstreamme · X

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma #science #publication #research #publications https://t.co/UiArVxfF9K

Sep 16, 2024 · 788 followers View post →

GeorgesMjaess

@GeorgesMjaess · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 1,115 followers View post →

SEOM

@_SEOM · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 34,256 followers View post →

たぬぽん

@west_east_NA · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 479 followers View post →

Stefania Colasanti

@Stefani19753108 · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 812 followers View post →

Stanley Leybourne GW

@stlenott · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 69 followers View post →

Stefania Colasanti

@Stefani19753108 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 812 followers View post →

Nick Liu, MD

@NickLiuMD · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 154 followers View post →

IntraMed Oncología

@IntraMedOnco · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 594 followers View post →

Harold Somerville

@haroldss1 · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 205 followers View post →

Florencia Sarrú

@SarruFlorencia · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 27 followers View post →

Laura Pelagatti

@laurapelagattis · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 62 followers View post →

MEDTRACK

@OncoReporte · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 949 followers View post →

Gil Morgan, MD

@weoncologists · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 16,327 followers View post →

OncoAlert

@OncoAlert · X

RT @RodRogSan: ⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 8 shares · 39,835 followers View post →

Rodrigo Sanchez Roger

@RodRogSan · X

⭕️Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR

Sep 16, 2024 · 10 likes · 8 shares · 743 followers View post →

tatsunori_shimoi 下井辰徳

@shimoi_oncology · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 1,306 followers View post →

Burak Alper Zengin

@dralperzeng · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 46 followers View post →

まる

@standardtherap · X

RT @NEJM: Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM…

Sep 16, 2024 · 11 shares · 2,640 followers View post →

NEJM

@NEJM · X

Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) https://t.co/1uM3K4ct6X #ESMO24 | @myESMO https://t.co/izjG0weLpW

Sep 16, 2024 · 26 likes · 11 shares · 935,606 followers View post →

Oncología en Twitts

@oncotwitts · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 1,308 followers View post →

HéctorÁlvarezA1

@hectoralvareza1 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 3,002 followers View post →

NCI CCR GU Malignancies

@nciccr_gmb · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 1,123 followers View post →

Jon Etxano

@jonetxano · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 163 followers View post →

Maxi Castro

@maxicastrovigo · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 16, 2024 · 123 shares · 1,295 followers View post →

Dr Maithily Gautam

@GautamMaithily · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 111 followers View post →

Dr. Amer Zahralliyali

@amersameer · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 5,983 followers View post →

CKY

@CKYSurOnc998188 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 313 followers View post →

Damian Silbermins

@nos3as · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 170 followers View post →

Marshall Strother

@mcstroth · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 499 followers View post →

Ippokratis Korantzis, Medical Oncologist, MD, PhD

@newsincancer · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/UrgRmGJ97X #ESMO2024

Sep 15, 2024 · 285 followers View post →

Enrique Gallardo

@EnriqueGallar12 · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 2,411 followers View post →

nel cuevas muñoz

@MunozNel · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 145 followers View post →

Objectif десму

@alexlefan · X

RT @NEJM: AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or obser…

Sep 15, 2024 · 123 shares · 1,616 followers View post →

Fuat Bicer MD, PhD

@fuatbcr · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/lTIFdOknsq

Sep 15, 2024 · 5 likes · 362 followers View post →

Top Biomedical Science

@imedverse · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma @NEJM #ESMO24 #CSCO24 @OncoAlert https://t.co/DDdZy9NCXz https://t.co/MzzFGK2koi https://t.co/nk9xXc0jTC

Sep 15, 2024 · 2 likes · 90,463 followers View post →

Albert Carrion

@A_Carrion_Puig · X

RT @dralvaropinto: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine http…

Sep 15, 2024 · 1 share · 1,395 followers View post →

Álvaro Pinto

@dralvaropinto · X

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/tRRDq3ykuq

Sep 15, 2024 · 1 like · 1 share · 3,479 followers View post →

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Carcinoma

Recent Advances in Bladder Cancer Treatment and Research Progress

Pembrolizumab Improves Outcomes in Muscle-Invasive Urothelial Carcinoma